Biothera Research Papers and presentations

Clinical, preclinical and analytical research with Biothera immune health ingredients:

 

July 2011

The Effects of Yeast β-Glucan Supplementation on Monocyte and Cytokine Response to Exercise.

Presented to the International Society of Exercise Immunology, University of Oxford, UK.

 

April 2011
Activation of the Innate Immune Receptor Dectin-1 upon Formation of a ‘Phagocytic Synapse’
Nature 472, 471–475 (28 April 2011) doi:10.1038/nature10071

 

April 2011

Baker’s Yeast Beta-Glucan Supplement Reduces Allergy Symptoms and Improves Quality of Life in Ragweed Sufferers

Presented to Experimental Biology 2011, Washington, D.C.

 

December 2010
A Randomised Controlled Trial to Assess the Ability of Yeast-Derived 1,3/1,6 Glucopolysaccharide to Reduce Upper Respiratory Tract Infection symptoms.
Presented to the British Society of Immunology, Liverpool, UK.

 

October 2010
Beta-Glucan Supplement Reduces URTIs & Improves Mood State in Stressed Women
Presented to the American College of Nutrition, New York, NY.

 

September 2010
Enzymatic Method To Measure β-1,3-β-1,6-Glucan Content in Extracts and Formulated Products (GEM Assay)
Journal of Agricultural and Food Chemistry. DOI:10.1021/jf102003m

 

April 2010

Beta-glucan Supplement Reduces Upper Respiratory Tract Infections and Improves Mood State in Healthy Stressed Subjects

Presented to Experimental Biology 2010, Anaheim, CA.

 

February 2010

Beta 1,3/1,6 Glucan Decreases Upper Respiratory Tract Infection Symptoms and Improves Psychological Well-being in Moderate to Highly-Stressed Subjects. 

Agro Food Industry Hi-Tech (2010). 21:21-24.

 

December 2009

Effect of Beta 1, 3/1, 6 Glucan on Upper Respiratory Tract Infection Symptoms and Mood State in Marathon Athletes

Journal of Sports Science and Medicine (2009). 8:509-515.

 

July 2009

Randomized Phase II Clinical Trials of Wellmune WGP® for Immune Support During Cold and Flu Season.

The Journal of Applied Research (2009). 9:20-42.

 

February 2009

Therapeutic potential of various β-glucan sources in conjunction with anti-tumor monoclonal antibody in cancer therapy.

Cancer Biology & Therapy 8:3, 216-223; 1 February 2009.

 

September 2008

Effects of an Immunomodulating Supplement on Upper Respiratory Tract Infection Symptoms in Wildland Firefighters.

Medicine & Science in Sports & Exercise. 40(5):S353.

 

August 2008
Analysis of Side Chain Lengths of Branched β-1,3-Glucans by Alkaline Degradation.
Presented to the International Carbohydrate Symposium, Oslo, Norway.

 

September 2007
Toxicological Assessment of a Particulate Yeast (1,3)-ß-D-Glucan in Rats.
Food and Chemical Toxicology (2007). 45:1719-1730.

 

August 2006

Yeast ß-Glucan Amplifies Phagocyte Killing of iC3b-Opsonized Tumor Cells via Complement Receptor 3-Syk-Phosphatidylinositol 3-Kinase Pathway.
The Journal of Immunology. 2006 Aug 1;177(3):1661-9

 

June 2005
C5a-Mediated Leukotriene B4-Amplified Neutrophil Chemotaxis is Essential in Tumor Immunotherapy Facilitated by Anti-Tumor Monoclonal Antibody and ß-Glucan.
The Journal of Immunology. 2005 174:7050-7056

 

May 2005
 Yeast Whole Glucan Particle ß-Glucan in Conjunction with Anti-tumour Monoclonal Antibodies to Treat Cancer.

Expert Opinion on Biological Therapy. May 2005, Vol. 5, No. 5, Pages 691-702

 

July 2004
Mechanism by Which Orally Administered ß-1,3-Glucans Enhance the Tumoricidal Activity of AntiTumor Monoclonal Antibodies in Murine Tumor Models.

The Journal of Immunology. 2004: 173: 797-806

 

March 2003
Anthrax-Protective Effects of Yeast Beta 1,3 Glucans.

Medscape General Medicine.

 

May 2002
Pilot Study: Orally-Administered Yeast ß1,3-glucan Prophylactically Protects Against Anthrax Infection and Cancer in Mice.
The Journal of the American Nutraceutical Association.
Vol. 5, No. 2, Spring 2002


Site design by Checkerboard